1. The Involvement of the Mammalian Target of Rapamycin, Protein Tyrosine Phosphatase 1b and Dipeptidase 4 Signaling Pathways in Cancer and Diabetes: A Narrative Review
   Jiajia Zhang et al, 2021, Mini-Reviews in Medicinal Chemistry CrossRef
2. CD26/DPP4 - a potential biomarker and target for cancer therapy
   Njanja Enz et al, 2019, Pharmacology & Therapeutics CrossRef
3. Saxagliptin defers thioacetamide-induced hepatocarcinogenesis in rats: A novel suppressive impact on Wnt/Hedgehog/Notch1 signaling
   Ahmed G. Abd Elhameed et al, 2021, Environmental Toxicology and Pharmacology CrossRef
4. Crosstalk between incretin hormones, Th17 and Treg cells in inflammatory diseases
   Eloisa Martins da Silva et al, 2022, Peptides CrossRef
5. Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials
   Ilaria Dicembrini et al, 2020, Acta Diabetologica CrossRef
6. Obesity and Cancer: Existing and New Hypotheses for a Causal Connection
   Trevor W. Stone et al, 2018, eBioMedicine CrossRef
7. Dipeptidyl Peptidase (DPP)-4 Inhibitor Impairs the Outcomes of Patients with Type 2 Diabetes Mellitus After Curative Resection for Colorectal Cancer
   Akira Saito et al, 2021, Cancer Research Communications CrossRef
8. Hepatocellular carcinoma: Mouse models and the potential roles of proteases
   James M. Henderson et al, 2017, Cancer Letters CrossRef
9. The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment
   Ze-Tao Zhan et al, 2022, Journal of Immunology Research CrossRef
10. Surface expression marker profile in colon cancer cell lines and sphere-derived cells suggests complexity in CD26+cancer stem cells subsets
    Lorena Vázquez-Iglesias et al, 2019, Biology Open CrossRef
11. Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants
    Zonglin Li et al, 2022, Expert Opinion on Investigational Drugs CrossRef
12. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, suppresses CXCL5 and SDF-1 and does not accelerate intestinal neoplasia formation in ApcMin/+ mice fed a high-fat diet
    Kaori Fujiwara et al, 2017, Oncology Letters CrossRef
13. Diabetes Mellitus and Colon Carcinogenesis: Expectation for Inhibition of Colon Carcinogenesis by Oral Hypoglycemic Drugs
    Junichi Kato et al, 2019, Gastrointestinal Disorders CrossRef
14. Effects of a DPP4 Inhibitor on Progression of NASH-related HCC and the p62/ Keap1/Nrf2-Pentose Phosphate Pathway in a Mouse Model
    Takumi Kawaguchi et al, 2019, Liver Cancer CrossRef
15. Inhibition of dipeptidyl peptidase IV prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2
    Chen-Jie Qin et al, 2018, Cancer Letters CrossRef
16. The mechanism of sitagliptin inhibition of colorectal cancer cell lines' metastatic functionalities
    Rubén Varela‐Calviño et al, 2021, IUBMB Life CrossRef
17. The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2/HO1 pathway
    Liang He et al, 2020, Medical Oncology CrossRef
18. Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?
    Petr Busek et al, 2022, Cancers CrossRef
19. Metformin Mitigates DPP-4 Inhibitor-Induced Breast Cancer Metastasis via Suppression of mTOR Signaling
    Emi Kawakita et al, 2021, Molecular Cancer Research CrossRef